MRNAModerna

On June 15, 2026, Abbas Hussain, one of our directors, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hussain 10b5-1 Plan). Beginning on May 6, 2027, the Hussain 10b5-1 Plan provides for a one-time sale of up to 2,930 shares of the Company’s common stock to satisfy tax obligations in connection with the vesting of an equity award. The Hussain 10b5-1 Plan expires on June 11, 2027, or upon the earlier completion of all authorized transactions under the Hussain 10b5-1 Plan.

Stephen Hoge, our President, has a stock option award to purchase 458,715 shares that will reach its ten-year expiration on February 23, 2027, and a stock option to purchase 1,834,862 shares that will reach its ten-year expiration on October 3, 2027 (together, the Hoge Expiring Options). On June 15, 2026, Dr. Hoge adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hoge 10b5-1 Plan). Between September 14, 2026, and September 17, 2027, the Hoge 10b5-1 Plan provides for (i) the exercise of 917,431 of the Hoge Expiring Options and the sale of the shares of common stock acquired upon exercise and (ii) the exercise of the rest of the Hoge Expiring Options and the sale of the number of shares of common stock necessary to cover the applicable exercise price, applicable withholding taxes, and related transaction costs. Dr. Hoge intends to retain the remaining shares of common stock acquired upon exercise. The Hoge 10b5-1 Plan expires on September 17, 2027, or upon the earlier completion of all authorized transactions under the plan.

On June 9, 2026, James Mock, our Chief Financial Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Mock 10b5-1 Plan). Between September 9, 2026 and March 1, 2027, the Mock 10b5-1 Plan provides for the potential sale of up to 15,000 shares of the Company’s common stock and for the potential exercise of vested stock options and the associated sale of up to 19,836 shares of the Company’s common stock. The Mock 10b5-1 Plan covers an aggregate maximum number of 34,836 shares of common stock. The Mock 10b5-1 Plan expires on March 1, 2027, or upon the earlier completion of all authorized transactions under the Mock 10b5-1 Plan.

On May 5, 2026, Shannon Klinger, our Chief Legal Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Klinger 10b5-1 Plan). Between September 8, 2026 and September 1, 2027, the Klinger 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 31,805 shares of the Company’s common stock. The Klinger 10b5-1 Plan expires on September 10, 2027, or upon the earlier completion of all authorized transactions under the Klinger 10b5-1 Plan.

On May 4, 2026, Stéphane Bancel, our Chief Executive Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c), which had been entered into on November 28, 2025, and was scheduled to commence as early as May 13, 2026, with a termination date of August 10, 2026. The plan provided for the potential sale of up to 751,715 shares of the Company’s common stock. No shares of common stock were sold under the plan prior to its termination. Mr. Bancel has two stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 558,394 shares and an option to purchase 193,321 shares. Mr. Bancel also has a stock option award to purchase 642,201 shares that will reach its ten-year expiration on February 23, 2027. Collectively, these awards are referred to as the “Bancel Expiring Options.” On May 4, 2026, Mr. Bancel adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between August 5, 2026, and February 26, 2027, the Bancel 10b5-1 Plan provides for the exercise of the Bancel Expiring Options and the sale of the number of shares of common stock necessary to cover the applicable exercise price, applicable withholding taxes, and related transaction costs. Mr. Bancel intends to retain the remaining shares of common stock acquired upon exercise. The Bancel 10b5-1 Plan expires on February 26, 2027, or upon the earlier completion of all authorized transactions under the plan.

Mr. Bancel has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 558,394 shares and another option to purchase 193,321 shares (the Bancel Expiring Options). Mr. Bancel intends to contribute all of the after-tax proceeds from the exercise and sale of the Bancel Expiring Options to charitable causes. On November 28, 2025, Mr. Bancel adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between May 13,2026 and August 10, 2026, the Bancel 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Bancel Expiring Options, which represent up to 751,715 shares of the Company’s common stock in the aggregate. The Bancel 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.

Stephen Hoge, our President, has two different stock option awards that will reach their ten-year expiration on August 10, 2026, including an option to purchase 223,357 shares and another option to purchase 96,660 shares (the Hoge Expiring Options). On November 13, 2025, Dr. Hoge adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hoge 10b5-1 Plan). Between February 23, 2026 and August 10, 2026, the Hoge 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Hoge Expiring Options, which represent up to 320,017 shares of the Company’s common stock in the aggregate. The Hoge 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the plan.

On September 9, 2025, Shannon Klinger, our Chief Legal Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Klinger 10b5-1 Plan). Between March 2, 2026 and September 4, 2026, the Klinger 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 20,827 shares of the Company’s common stock. The Klinger 10b5-1 Plan expires on September 4, 2026, or upon the earlier completion of all authorized transactions under the Klinger 10b5-1 Plan.

On September 5, 2025, Abbas Hussain, one of our directors, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hussain 10b5-1 Plan). Between December 9, 2025 and April 30, 2026, the Hussain 10b5-1 Plan provides for the sale of up to 6,186 shares of the Company’s common stock to satisfy tax obligations in connection with the vesting of equity awards. The Hussain 10b5-1 Plan expires on April 30, 2026, or upon the earlier completion of all authorized transactions under the Hussain 10b5-1 Plan.

St é phane Bancel, our Chief Executive Officer, has three different stock option awards that will reach their ten-year expiration in 2026, including 688,073 options that will expire on February 23, 2026, 558,394 options that will expire on August 10, 2026, and another 193,321 options that also expire on August 10, 2026 (the Expiring Options). Mr. Bancel intends to contribute all of the after-tax proceeds from the exercise and sale of the Expiring Options to charitable causes. On September 3, 2025, Mr. Bancel adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between December 17, 2025 and August 10, 2026, the Bancel 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of the Expiring Options, which represent up to 1,439,788 shares of the Company’s common stock. The Bancel 10b5-1 Plan expires on August 10, 2026, or upon the earlier completion of all authorized transactions under the Bancel 10b5-1 Plan.

On March 13, 2025, Abbas Hussain, one of our directors, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Hussain 10b5-1 Plan). The Hussain 10b5-1 Plan provides for the sale on June 11, 2025 of up to 313 shares of the Company’s common stock to satisfy tax obligations in connection with the vesting of equity awards. The Hussain 10b5-1 Plan expires on June 30, 2025, or upon the earlier completion of all authorized transactions under the Hussain 10b5-1 Plan.

On November 8, 2024, Stephane Bancel, our Chief Executive Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). The Bancel 10b5-1 Plan was entered into on June 10, 2024, and was scheduled to commence as early as September 25, 2024, with a termination date of February 27, 2025. The Bancel 10b5-1 Plan provided for the potential sale of up to 150,000 shares of common stock. No shares of common stock were sold under the Bancel 10b5-1 Plan prior to its termination.

On June 10, 2024, Shannon Klinger, our Chief Legal Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Klinger 10b5-1 Plan). Between September 12, 2024 and August 15, 2025, the Klinger 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 73,086 shares of the Company’s common stock. The Klinger 10b5-1 Plan expires on August 15, 2025, or upon the earlier completion of all authorized transactions under the Klinger 10b5-1 Plan.

On June 10, 2024, Stephane Bancel, our Chief Executive Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). Between September 25, 2024 and February 27, 2025, the Bancel 10b5-1 Plan provides for the potential sale of up to 150,000 shares of the Company’s common stock. The Bancel 10b5-1 Plan expires on February 27, 2025, or upon the earlier completion of all authorized transactions under the Bancel 10b5-1 Plan.

On November 7, 2023, Noubar Afeyan, our Chairman, amended a trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Afeyan 10b5-1 Plan). The Afeyan 10b5-1 Plan was amended to increase certain price triggers under the plan. The Afeyan 10b5-1 Plan, as amended, is scheduled to commence on February 28, 2024, and will run through August 20, 2025 . The aggregate maximum number of shares of common stock that may be sold pursuant to the Afeyan 10b5-1 Plan is 745,000, which represents the shares remaining under the original plan that have not been sold to date .

On November 6, 2023, Arpa Garay, our former Chief Commercial Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Garay 10b5-1 Plan). The Garay 10b5-1 Plan was entered into on August 24, 2023, and was scheduled to commence on November 27, 2023, with a termination date of August 30, 2024. The Garay 10b5-1 Plan provided for the potential sale of approximately 4,540 shares of common stock and for the potential exercise of vested stock options and the associated sale of up to 24,897 shares. No shares of common stock were sold, and no options to purchase shares of common stock were exercised, under the Garay 10b5-1 Plan prior to its termination.

On August 24, 2023, Arpa Garay, our Chief Commercial Officer, adopted a trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Garay 10b5-1 Plan). Between November 27, 2023 and August 30, 2024, the Garay 10b5-1 Plan provides for the potential sale of approximately 4,540 shares of the Company’s common stock and for the potential exercise of vested stock options and the associated sale of up to 24,897 shares. The plan expires on August 30, 2024, or upon the earlier completion of all authorized transactions under the plan.

On August 11, 2023, Stephane Bancel, our Chief Executive Officer, terminated a trading arrangement that was intended to satisfy the affirmative defense of Rule 10b5-1(c) (the Bancel 10b5-1 Plan). The Bancel 10b5-1 Plan was entered into on March 7, 2023, and was scheduled to commence on September 6, 2023, with a termination date of the earlier of August 29, 2025 or the date all shares under the plan were sold. The aggregate number of securities to be sold pursuant to the Bancel 10b5-1 Plan was 1,200,000.